The blockade of immune checkpoints in cancer immunotherapy

2012/03/22 by Drew M. Pardoll · 8 citations
Immunology and Microbiology · Medicine · #Antibody #Antigen #Biology #Blockade #CAR-T cell therapy research #Cancer Immunotherapy and Biomarkers #Cancer immunotherapy #Cancer research #Collateral damage #Cytotoxic T cell #Immune Cell Function and Interaction #Immune checkpoint #Immune system #Immune tolerance #Immunity #Immunology #Immunotherapy #In vitro #Peripheral tolerance #Receptor

paper · pdf · doi:10.1038/nrc3239

crossref issued 2012/03/22 · crossref published 2012/03/22 · crossref published-online 2012/03/22 · openalex publication_date 2012/03/22 · crossref created 2012/03/23 · crossref published-print 2012/04/01 · crossref deposited 2025/04/11 · openalex created_date 2025/10/10 · openalex updated_date 2026/08/06 · crossref indexed 2026/08/07

Citations

• Control of Regulatory T Cell Development by the Transcription Factor Foxp3
• Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
• Combining immunotherapy and targeted therapies in cancer treatment
• Foxp3 programs the development and function of CD4+CD25+ regulatory T cells

Cited by

• Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
• PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
• Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications
• Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic
• Spotlight on pembrolizumab in non-small cell lung cancer: the evidence to date
• Multimodal pooled Perturb-CITE-seq screens in patient models define mechanisms of cancer immune evasion
• First line Immunotherapy for Non-Small Cell Lung Cancer
• Pembrolizumab [wikipedia]